The aim of this study was to determine the performance of antibodies against mutated citrullinated vimentin (anti-MCV) in comparison with antibodies to cyclic citrullinated peptides (anti-CCP) in patients with rheumatoid arthritis (RA). Serum levels of anti-MCV and anti-CCP were determined in 193 patients with RA and 332 controls, and sensitivity and specificity were calculated. In a separate analysis of 86 patients, the anti-MCV levels were compared to disease activity. Sensitivity of anti-MCV versus anti-CCP was 71.5 and 69.4%, specificity was 81.3 and 97.6%, respectively. The ROC curves showed higher specificity and an advantage of anti-CCP. In seronegative RA patients the sensitivity of anti-MCV was superior over anti-CCP. Anti-MCV positivities also occurred in systemic lupus erythematosus and Sjoegren’s syndrome. In a subgroup of 86 RA patients we found a significant correlation between anti-MCV and disease activity. Anti-MCV appears to be an important marker for the diagnosis of RA, and correlates also with disease activity.
Anti-mutated citrullinated vimentinRheumatoid arthritisInflammatory rheumatic diseasesSensitivity and specificity
1.Institute for Rheumatology of the Kurstadt Baden RSKA Baden of the NOEGKK and Ludwig Boltzmann Cluster Rheumatology, Balneology and RehabilitationForschungsstelle for Epidemiology of Rheumatic DiseasesBadenAustria
2.Institute for Rheumatology of the Kurstadt Baden 4th Medical Department and Ludwig Boltzmann Institute of Osteology, Hanusch Krankenhaus of WGKKViennaAustria